Comprehensive Genomic Profiling Broadens Treatment Options in Community Care

Comprehensive genomic profiling (CGP) incorporating advanced sequencing features may expand treatment options for patients with cancer treated in community oncology settings, according to a study recently published in JCO Precision Oncology.¹

Findings suggest that specific platform capabilities such as tumor-normal matched sequencing, RNA sequencing, and liquid biopsy reflex testing contribute meaningfully to therapeutic decision-making and clinical trial access. Specifically, of 85 patients treated in a value-based community setting, clinically actionable alterations were identified in up to nearly half (49%) of patients. In a larger retrospective cohort of patients (n = 465), such alterations were detected in 31%.

“Our study indicates that the enhanced features of specific CGP platforms—including tumor-normal matched tissue testing, RNA [sequencing], and reflex testing—substantially affect patient care options,” authors Paul La Porte, MD, PhD and colleagues wrote.¹ “Payers should thoroughly examine components of CGP assays, as their decisions could greatly affect the level of care delivered to patients, particularly when less comprehensive tests are chosen.”

Study Design and Population

The analysis included 2 cohorts: a prospective pilot cohort of 85 patients treated in a community oncology network, and a retrospective cohort of 465 patients with solid tumors. All patients underwent next-generation sequencing (NGS)–based CGP using a commercial platform. Actionable findings were defined as genomic alterations linked to FDA-approved therapies, tumor mutational burden–high, microsatellite instability–high, or pathogenic germline variants.¹

Clinical Trial Matching and Enrollment

Integration of CGP with a Just-in-Time clinical trial matching system facilitated identification of trial opportunities. Among 465 patients in the expanded cohort, 87 were matched to potential trials, and 3 were ultimately enrolled. The median time to trial activation ranged from 10 to 18 days.

Although enrollment rates were modest, the authors note that access to trial matching infrastructure within community settings may improve participation, particularly for patients who would otherwise lack access to academic centers.

Barriers to Implementation

Despite guideline support from organizations such as the American Society of Clinical Oncology (ASCO) and National Comprehensive Cancer Network (NCCN), CGP adoption in community oncology remains variable. Prior studies indicate that a substantial proportion of oncologists order NGS testing for a minority of eligible patients, with insurance denials representing a significant barrier.²

In the pilot cohort, of 72 evaluable patients, insurance authorization for CGP testing was denied in approximately 59% of cases. Notably, 50% of these denied cases still yielded actionable findings when testing was performed, suggesting that payer restrictions may limit access to clinically meaningful information.

Implications for Value-Based Care

The study situates CGP within a value-based care framework, emphasizing its potential to improve outcomes while optimizing resource utilization. By identifying actionable alterations and avoiding ineffective therapies, CGP may reduce treatment-related toxicity and unnecessary costs. Additionally, comprehensive platforms that integrate molecular and clinical data may enhance diagnostic accuracy, risk stratification, and treatment selection. These capabilities are particularly relevant in community oncology settings, where access to subspecialized molecular expertise may be limited.

The authors acknowledge limitations, including the retrospective nature of the expanded cohort and the inability to attribute specific findings to individual assay components in all cases. Selection bias and variability in clinical decision-making may also influence results. According to the authors, prospective studies may further clarify the impact of CGP-guided therapy on survival and quality of life in community oncology settings.

REFERENCES

1. La Porte P, Ashok A, Sweeney NW, et al. Unique features of a comprehensive genomic profiling panel: Expanding treatment options in a value-based community oncologynetwork. JCO Precis Oncol. 2026;10(3):e2500623. doi:10.1200/PO-25-00623

2. Sheinson DM, Wong WB, Meyer CS, et al. Trends in use of next-generation sequencing in patients with solid tumors by race and ethnicity after implementation of the Medicare National Coverage Determination. JAMA Netw Open. 2021;4(12):e2138219. Published 2021 Dec 1. doi:10.1001/jamanetworkopen.2021.38219